Ignite Creation Date:
2025-12-24 @ 4:16 PM
Ignite Modification Date:
2026-04-18 @ 6:44 PM
Study NCT ID:
NCT03317366
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2021-08-06
First Post:
2017-10-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization: